LIVN on Nasdaq
LivaNova
Italian-American medical device manufacturer
LivaNova, plc is a medical device manufacturer that is a foreign domiciled company based in the U.K. for tax inversion purposes. With operational headquarters in the United States.3 Its shares trade on Nasdaq under the symbol LIVN.1 Wikipedia text CC BY-SA 4.0
Price unavailable
Last updated Oct 21, 2026.
Overview
2015Founded1
Compare with CONMED Corporation, Integer or TransMedics Group, Inc., or pick any stock.
- TickerLIVN on Nasdaq1
- IndustryElectromedical & Electrotherapeutic Apparatus1
- HeadquartersLondon1
- Founded inLondon1
- Websitewww.livanova.com
- Legal formpublic limited company1
- Incorporated inUnited Kingdom5
- Business address5220 Valiant Court, Gloucester Business Park, Gloucester5
- Filer categoryLarge accelerated filer5
- LEI2138001K2FX6SHK2B3394
- StatusActive4
- LEI statusLapsed (not renewed)4
- Registered address20 EASTBOURNE TERRACE, W2 6LG London, United Kingdom4
- Registered withCompanies House, 094513744
See how the biggest companies compare on our leaderboards
LivaNova, plc is a medical device manufacturer that is a foreign domiciled company based in the U.K. for tax inversion purposes. With operational headquarters in the United States.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
67.7%Gross margin7
14.4%Operating margin7
-17.5%Net margin7
10.7%Revenue growth, 20257
-20.2%Return on equity7
0.29×Debt to equity7
$173.3MFree cash flow7
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
Cardiopulmonary brought in 57% of the revenue LivaNova broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cardiopulmonary | $604.1M | $683.5M | $785.4M |
| Neuromodulation | $519.7M | $554.2M | $592.8M |
Regions
United States brought in 51% of the revenue LivaNova broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $635.0M | $695.1M | $739.6M |
| Locations Excluding The United States And Europe | $303.7M | $338.3M | $379.3M |
| Europe | $214.8M | $220.0M | $269.2M |
| United Kingdom | $41.5M | $48.9M | $55.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue32¢$448.2M
- Research and development13¢$185.8M
- Selling, general and admin40¢$548.8M
- Other costs13¢$183.7M
- Income tax2¢$21.6M
Out of $1.4B in revenue.7 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending32¢$81.0M
- Kept or used elsewhere68¢$173.3M
Out of $254.3M of cash from operations.7
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net revenue | $1.4B | $1.3B | $1.2B |
| Cost of sales | $448.2M | $400.0M | $397.7M |
| Gross profit | $939.9M | $853.5M | $755.8M |
| Selling, general, and administrative | $548.8M | $508.9M | $502.7M |
| Research and development | $185.8M | $182.5M | $193.8M |
| Impairment of long-lived assets | $0 | $0 | $90.0M |
| Other operating expense | $5.9M | $33.0M | $37.8M |
| Operating income (loss) | $199.4M | $129.1M | -$68.5M |
| SNIA environmental liability expense | -$365.6M | $0 | $0 |
| Interest expense | -$49.3M | -$63.1M | -$58.9M |
| Loss on debt extinguishment | -$2.7M | -$25.5M | $0 |
| Foreign exchange and other income/(expense) | -$2.7M | $47.8M | $46.1M |
| (Loss) income before income tax | -$220.8M | $88.3M | -$81.2M |
| Income tax expense (benefit) | $21.6M | $25.1M | -$98.9M |
| Loss from equity method investments | -$51.0K | -$18.0K | -$104.0K |
| Net (loss) income | -$242.5M | $63.2M | $17.5M |
| Basic (loss) income per share (in dollars per share) | -$4.45 | $1.17 | $0.33 |
| Diluted (loss) income per share (in dollars per share) | -$4.45 | $1.16 | $0.32 |
| Shares used in computing basic (loss) income per share (in shares) | 54.5M shares | 54.2M shares | 53.9M shares |
| Shares used in computing diluted (loss) income per share (in shares) | 54.5M shares | 54.6M shares | 54.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $635.6M | $428.9M | $266.5M | |
| Restricted cash | $0 | $294.7M | $311.4M | |
| Accounts receivable, net of allowance of $12,527 as of December 31, 2025 and $11,275 as of December 31, 2024 | $216.0M | $193.2M | ||
| Inventories | $164.7M | $147.6M | ||
| Prepaid and refundable taxes | $48.6M | $30.5M | ||
| Prepaid expenses and other current assets | $36.8M | $32.4M | ||
| Total Current Assets | $1.1B | $1.1B | ||
| Property, plant, and equipment, net | $242.6M | $170.3M | ||
| Goodwill | $792.8M | $750.0M | $782.9M | |
| Intangible assets, net | $230.0M | $237.3M | ||
| Operating lease assets | $55.5M | $46.8M | ||
| Investments | $20.3M | $25.1M | ||
| Deferred tax assets | $111.0M | $111.9M | ||
| Long-term derivative assets | $36.6M | $23.7M | ||
| Other assets | $15.7M | $14.1M | ||
| Total Assets | $2.6B | $2.5B | ||
| Current debt obligations | $31.5M | $78.0M | ||
| Accounts payable | $97.2M | $69.7M | ||
| Accrued liabilities and other | $94.6M | $118.5M | ||
| SNIA environmental liability | $396.2M | $0 | ||
| Current contingent consideration | $50.0M | $0 | ||
| Current litigation provision liability | $12.6M | $12.9M | ||
| Taxes payable | $33.1M | $32.5M | ||
| Accrued employee compensation and related benefits | $92.9M | $80.5M | ||
| Total Current Liabilities | $808.1M | $392.1M | ||
| Long-term debt obligations | $345.2M | $549.6M | ||
| Long-term contingent consideration | $42.0M | $84.2M | ||
| Deferred tax liabilities | $9.6M | $10.9M | ||
| Long-term operating lease liabilities | $48.3M | $40.1M | ||
| Long-term employee compensation and related benefits | $13.6M | $12.8M | ||
| Long-term derivative liabilities | $83.9M | $51.8M | ||
| Other long-term liabilities | $55.4M | $44.5M | ||
| Total Liabilities | $1.4B | $1.2B | ||
| Ordinary Shares, 1.00 par value: Unlimited shares authorized; 55,535,181 shares issued and 54,649,085 shares outstanding as of December 31, 2025; 54,437,670 shares issued and 54,348,542 shares outstanding as of December 31, 2024 | $84.6M | $83.2M | ||
| Additional paid-in capital | $2.3B | $2.2B | ||
| Accumulated other comprehensive income (loss) | $7.3M | -$80.2M | ||
| Accumulated deficit | -$1.1B | -$903.2M | ||
| Treasury shares at cost, 886,096 ordinary shares as of December 31, 2025; 89,128 ordinary shares as of December 31, 2024 | -$1.2M | -$136.0K | ||
| Total Shareholders Equity | $1.2B | $1.3B | $1.3B | $1.2B |
| Total Liabilities and Shareholders Equity | $2.6B | $2.5B | ||
| Allowance for doubtful accounts | $12.5M | $11.3M | ||
| Ordinary shares, par value (in pounds per share) | 1.00 GBP | 1.00 GBP | ||
| Ordinary shares issued (in shares) | 55.5M shares | 54.4M shares | ||
| Ordinary shares outstanding (in shares) | 54.6M shares | 54.3M shares | ||
| Treasury shares (in shares) | 886.1K shares | 89.1K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $635.6M | $428.9M | $266.5M | |
| Restricted cash | $0 | $294.7M | $311.4M | |
| Accounts receivable, net of allowance of $12,527 as of December 31, 2025 and $11,275 as of December 31, 2024 | $216.0M | $193.2M | ||
| Inventories | $164.7M | $147.6M | ||
| Prepaid and refundable taxes | $48.6M | $30.5M | ||
| Prepaid expenses and other current assets | $36.8M | $32.4M | ||
| Total Current Assets | $1.1B | $1.1B | ||
| Property, plant, and equipment, net | $242.6M | $170.3M | ||
| Goodwill | $792.8M | $750.0M | $782.9M | |
| Intangible assets, net | $230.0M | $237.3M | ||
| Operating lease assets | $55.5M | $46.8M | ||
| Investments | $20.3M | $25.1M | ||
| Deferred tax assets | $111.0M | $111.9M | ||
| Long-term derivative assets | $36.6M | $23.7M | ||
| Other assets | $15.7M | $14.1M | ||
| Total Assets | $2.6B | $2.5B | ||
| Current debt obligations | $31.5M | $78.0M | ||
| Accounts payable | $97.2M | $69.7M | ||
| Accrued liabilities and other | $94.6M | $118.5M | ||
| SNIA environmental liability | $396.2M | $0 | ||
| Current contingent consideration | $50.0M | $0 | ||
| Current litigation provision liability | $12.6M | $12.9M | ||
| Taxes payable | $33.1M | $32.5M | ||
| Accrued employee compensation and related benefits | $92.9M | $80.5M | ||
| Total Current Liabilities | $808.1M | $392.1M | ||
| Long-term debt obligations | $345.2M | $549.6M | ||
| Long-term contingent consideration | $42.0M | $84.2M | ||
| Deferred tax liabilities | $9.6M | $10.9M | ||
| Long-term operating lease liabilities | $48.3M | $40.1M | ||
| Long-term employee compensation and related benefits | $13.6M | $12.8M | ||
| Long-term derivative liabilities | $83.9M | $51.8M | ||
| Other long-term liabilities | $55.4M | $44.5M | ||
| Total Liabilities | $1.4B | $1.2B | ||
| Ordinary Shares, 1.00 par value: Unlimited shares authorized; 55,535,181 shares issued and 54,649,085 shares outstanding as of December 31, 2025; 54,437,670 shares issued and 54,348,542 shares outstanding as of December 31, 2024 | $84.6M | $83.2M | ||
| Additional paid-in capital | $2.3B | $2.2B | ||
| Accumulated other comprehensive income (loss) | $7.3M | -$80.2M | ||
| Accumulated deficit | -$1.1B | -$903.2M | ||
| Treasury shares at cost, 886,096 ordinary shares as of December 31, 2025; 89,128 ordinary shares as of December 31, 2024 | -$1.2M | -$136.0K | ||
| Total Shareholders Equity | $1.2B | $1.3B | $1.3B | $1.2B |
| Total Liabilities and Shareholders Equity | $2.6B | $2.5B | ||
| Allowance for doubtful accounts | $12.5M | $11.3M | ||
| Ordinary shares, par value (in pounds per share) | 1.00 GBP | 1.00 GBP | ||
| Ordinary shares issued (in shares) | 55.5M shares | 54.4M shares | ||
| Ordinary shares outstanding (in shares) | 54.6M shares | 54.3M shares | ||
| Treasury shares (in shares) | 886.1K shares | 89.1K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net (loss) income | -$242.5M | $63.2M | $17.5M |
| Share-based compensation | $36.3M | $33.9M | $36.4M |
| Depreciation | $28.6M | $25.1M | $24.7M |
| Amortization of debt issuance costs | $23.1M | $21.6M | $19.1M |
| Amortization | $17.7M | $17.2M | $25.5M |
| Amortization of operating lease assets | $13.4M | $8.8M | $10.6M |
| Remeasurement of contingent consideration to fair value | $7.9M | $3.3M | $9.4M |
| Remeasurement of derivative instruments, net | -$6.9M | -$25.3M | -$22.9M |
| Gain on sale of asset | -$4.1M | $0 | $0 |
| Loss (gain) on investment revaluation - Ceribell, Inc. | $3.6M | -$7.1M | $0 |
| Loss on debt extinguishment | $2.7M | $25.5M | $0 |
| Deferred income tax expense (benefit) | $455.0K | $6.8M | -$114.4M |
| Impairment of investments | $1.1M | $5.8M | $0 |
| Impairment of long-lived assets | $0 | $0 | $90.0M |
| ACS inventory obsolescence adjustment | $0 | $0 | $12.6M |
| Other | $3.2M | $3.0M | $1.1M |
| Accounts receivable, net | -$10.7M | $11.1M | -$28.9M |
| Inventories | -$5.3M | -$6.8M | -$28.5M |
| Other current and non-current assets | $38.5M | -$1.6M | $15.3M |
| Accounts payable and accrued current and non-current liabilities | -$13.4M | -$14.5M | $19.2M |
| Taxes payable | -$3.6M | $10.9M | $7.4M |
| SNIA environmental liability | $365.6M | $0 | $0 |
| Litigation provision liability | -$1.1M | $2.3M | -$19.1M |
| Net cash provided by operating activities | $254.3M | $183.0M | $74.9M |
| Purchases of property, plant, and equipment | -$81.0M | -$47.1M | -$35.0M |
| Proceeds from sale of investment | $6.5M | $0 | $0 |
| Proceeds from asset sales | $7.3M | $89.0K | $1.2M |
| Purchases of investments | -$5.7M | -$1.1M | -$6.5M |
| Net cash used in investing activities | -$72.9M | -$48.2M | -$40.3M |
| Repayment of long-term debt obligations | -$280.9M | -$247.5M | -$21.6M |
| Shares repurchased from employees for minimum tax withholding | -$4.4M | -$8.4M | -$7.5M |
| Proceeds from exercise of stock options | $35.0K | $6.3M | $19.0K |
| Proceeds from long-term debt obligations | $0 | $335.5M | $50.0M |
| Payment of debt extinguishment costs | $0 | -$39.0M | $0 |
| Purchase of capped calls | $0 | -$31.6M | $0 |
| Proceeds from unwind of capped calls | $0 | $22.5M | $0 |
| Payment of contingent consideration | $0 | -$13.8M | $0 |
| Payment of debt issuance costs | $0 | -$5.9M | $0 |
| Other | -$338.0K | $438.0K | $592.0K |
| Net cash (used in) provided by financing activities | -$285.7M | $18.6M | $21.5M |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | $16.2M | -$7.7M | $6.2M |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -$88.0M | $145.7M | $62.3M |
No quarter-by-quarter statement was filed.
Corporate structure
LivaNova sits at the top of its group. 35 entities, 28 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of LivaNova
- FMR LLC Filed SCHEDULE 13G on LivaNova, latest Aug 6, 2026
- INTEGRATED CORE STRATEGIES (US) LLC Filed SCHEDULE 13G/A on LivaNova, latest Apr 30, 2026 (5 filings since Apr 17, 2024)
- PRIMECAP MANAGEMENT CO/CA/ Filed SCHEDULE 13G/A on LivaNova, latest Feb 12, 2026 (6 filings since Feb 10, 2022)
- BlackRock Filed SCHEDULE 13G/A on LivaNova, latest Jul 18, 2025 (6 filings since Jan 26, 2022)
- HARRIS ASSOCIATES L P Filed SC 13G/A on LivaNova, latest Feb 14, 2023 (2 filings since Feb 11, 2022)
- LivaNova London, United Kingdom
- Cyberonics Netherlands CV Subsidiary · Netherlands
- LivaNova (China) Medical Technology Co. Ltd Subsidiary · China
- LivaNova (Thailand) Ltd Subsidiary · Thailand
- LivaNova Australia PTY Limited Subsidiary · Australia
- LivaNova Austria GmbH Subsidiary · Austria
- LivaNova Belgium N.V. Subsidiary · Belgium
- LivaNova Brasil Comércio e Distribuição de Equipamentos Médico-hospitalares Ltda Subsidiary · Brazil
- LivaNova Canada, Inc. Subsidiary · Canada
- LivaNova Chile SpA Subsidiary · Chile
- LivaNova Colombia Sas Subsidiary · Colombia
- LivaNova Deutschland GmbH Subsidiary · Germany
- LivaNova Espana, S.L. Subsidiary · Spain
- LivaNova Finland Oy Subsidiary · Finland
- LivaNova Holding S.r.l. Subsidiary · Italy
- LivaNova Hong Kong Limited Subsidiary · Hong Kong
- LIVANOVA INDIA PRIVATE LIMITED Subsidiary · Gurgaon, India
- LivaNova IP Limited Subsidiary · United Kingdom
- LivaNova Japan K.K. Subsidiary · Japan
- LivaNova Malaysia Sdn. Bhd. Subsidiary · Malaysia
- LivaNova Nederland N.V. Subsidiary · Netherlands
- LivaNova Norway AS Subsidiary · Norway
- LivaNova Plc (Italian Branch) Subsidiary · Italy
- LivaNova Poland Sp. Z o.o. Subsidiary · Poland
- LivaNova Regional Headquarter Company Subsidiary · Saudi Arabia
- LivaNova Singapore Pte Ltd Subsidiary · Singapore
- and 9 more
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What LivaNova reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $484.8M7 Dec 31, 2025 | $377.0M7 Dec 31, 2024 | +28.6% |
| Accumulated depreciation | $242.2M7 Dec 31, 2025 | $206.8M7 Dec 31, 2024 | +17.1% |
| Property and equipment, net | $242.6M7 Dec 31, 2025 | $170.3M7 Dec 31, 2024 | +42.5% |
| Operating-lease assets (leased space) | $55.5M7 Dec 31, 2025 | $46.8M7 Dec 31, 2024 | +18.5% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $635.6M7 Dec 31, 2025 | $428.9M7 Dec 31, 2024 | +48.2% |
| Stakes in other companies (equity method) | $6.8M7 Dec 31, 2025 | $3.7M7 Dec 31, 2024 | +83.3% |
| Long-term investments | $20.3M7 Dec 31, 2025 | $25.1M7 Dec 31, 2024 | −19.1% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $792.8M7 Dec 31, 2025 | $750.0M7 Dec 31, 2024 | +5.7% |
| Intangible assets, net (excluding goodwill) | $230.0M7 Dec 31, 2025 | $237.3M7 Dec 31, 2024 | −3.1% |
| Finite-lived intangibles, gross | $314.9M7 Dec 31, 2025 | $289.6M7 Dec 31, 2024 | +8.7% |
| Accumulated amortization | $196.9M7 Dec 31, 2025 | $164.4M7 Dec 31, 2024 | +19.8% |
| Finite-lived intangibles, net | $118.0M7 Dec 31, 2025 | $125.3M7 Dec 31, 2024 | −5.9% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $164.7M7 Dec 31, 2025 | $147.6M7 Dec 31, 2024 | +11.6% |
| Raw materials | $75.8M7 Dec 31, 2025 | $71.9M7 Dec 31, 2024 | +5.4% |
| Work in process | $12.9M7 Dec 31, 2025 | $12.3M7 Dec 31, 2024 | +4.5% |
| Finished goods | $76.0M7 Dec 31, 2025 | $63.3M7 Dec 31, 2024 | +20.1% |
Properties, in its own words
LivaNova’s principal executive office is located in the UK and is leased by the Company. LivaNova’s business segments are headquartered in the U.S. for Neuromodulation and in Italy for Cardiopulmonary. LivaNova has manufacturing facilities located in the U.S., Italy, Germany, Australia, and Brazil, and research facilities in the U.S. and Italy. The Company’s
manufacturing and research facilities total approximately 1.0 million square feet. The manufacturing and research facilities located in the U.S., Italy, and Brazil are owned by LivaNova. 44% of LivaNova’s manufacturing and research facilities by square feet are located within the U.S., 56% of LivaNova’s manufacturing and research facilities by square feet are owned by the Company, and the balance is leased.
The rest of Item 2
LivaNova also maintains 28 primary administrative offices in 20 countries. Most of these locations are leased. LivaNova is using substantially all of the Company’s currently available productive space to develop, manufacture, and market LivaNova’s products. LivaNova believes that all of its facilities are in good operating condition, suitable for their respective uses, and adequate for current needs.
Item 2 of the 10-K filed Feb 25, 2026.15
Leadership
Who has led LivaNova, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
20202025
- Chief executive officerVladimir Makatsaria Mar 4, 2024 to now16
- Chief executive officerWilliam A. Kozy Dec 19, 2023 to Mar 4, 202417
- Chief executive officerDamien McDonald Nov 8, 2016 to Apr 28, 202318
- Chief executive officerAndre Michel Ballester Oct 22, 2015 to Jan 4, 201719
- ChairWilliam A. Kozy Dec 19, 2023 to Mar 4, 202417
- PresidentStefano Folli Aug 5, 2026 to now20
- PresidentStephanie Bolton Mar 11, 2024 to Aug 9, 202421
- PresidentFranco Poletti Aug 9, 2024 to Aug 5, 202622
- PresidentMarco Dolci Apr 1, 2022 to Apr 3, 202323
- PresidentRoy Khoury Jan 10, 2020 to Mar 3, 202124
- PresidentRobert Jason Richey Jan 21, 2016 to Jul 29, 201625
- PresidentJacques Gutedel Mar 1, 2016 to Aug 11, 201626
- PresidentMichel Darnaud Oct 22, 2015 to Jul 29, 201627
- PresidentRohan Hoare Oct 22, 2015 to Oct 27, 201528
- Chief financial officerAlex Shvartsburg Nov 6, 2020 to now29
- Chief financial officerThad Allen Huston May 22, 2017 to May 27, 202030
- Chief financial officerVivid Sehgal Oct 22, 2015 to Mar 14, 201731
- Chief operating officerDamien McDonald Oct 7, 2016 to Oct 7, 201632
Board members and other officers (35)
- Chief Human Resources OfficerNatalia Kozmina Jan 17, 2025 to now33
- Chief Innovation OfficerAhmet Tezel May 17, 2024 to now34
- SVP Global Operations, R&DMarco Dolci Jan 10, 2020 to Mar 17, 202235
- General Manager, CSAlistair Simpson Jan 2, 2019 to Jan 7, 202036
- Chief Human Resources OfficerTrui Hebbelinck Apr 26, 2019 to Apr 2, 202437
- Chief Accounting OfficerDouglas J. Manko Jul 12, 2016 to Apr 1, 202038
- SR VP Genl Counsel & SecretaryBrian Sheridan Oct 22, 2015 to Mar 17, 201639
- Chief Integration OfficerDemetrio Mauro Oct 22, 2015 to Jan 5, 201640
- SR VP Strategy & Bus DevEdward Andrle Oct 22, 2015 to Jan 7, 202041
- Pres Cardiac Rhythm MgmtLullo Stefano Di Oct 22, 2015 to Jul 29, 201642
- VP & ControllerPiero Vecchi Oct 22, 2015 to Jul 29, 201643
- SR VP Global Market AccessPritpal Shinmar Oct 22, 2015 to Jul 29, 201644
- Board memberJette Nygaard-Andersen Jun 11, 2026 to now45
- Board memberDonald Zurbay Sep 4, 2025 to now46
- Board memberVladimir Makatsaria Mar 4, 2024 to now16
- Board memberSusan M. Podlogar Oct 15, 2024 to now47
- Board memberDamien McDonald Apr 3, 2023 to Apr 28, 202348
- Board memberPeter M. Wilver Jun 17, 2022 to now49
- Board memberBrooke Story Sep 19, 2022 to now50
- Board memberTodd Schermerhorn Dec 8, 2020 to now51
- Board memberSeng Stacy Enxing Jun 20, 2019 to now52
- Board memberWilliam A. Kozy Jun 18, 2018 to now53
- Board memberArthur L. Rosenthal Jun 16, 2016 to Jun 17, 202254
- Board memberAndrea L. Saia Jul 29, 2016 to Jan 3, 202455
- Board memberAlfred J. Novak Oct 22, 2015 to Jun 17, 202256
- Board memberAndre Michel Ballester Oct 22, 2015 to Mar 17, 201619
- Board memberDaniel Jeffrey Moore Oct 22, 2015 to Jun 5, 202457
- Board memberFrancesco Bianchi Oct 22, 2015 to now58
- Board memberHugh M. Morrison Oct 22, 2015 to Jul 1, 202159
- Board memberRosario Bifulco Oct 22, 2015 to Oct 22, 201560
- Board memberSharon O'Kane Oct 22, 2015 to now61
- Board memberStefano Gianotti Oct 22, 2015 to Mar 27, 201862
- General counselAnne M. Liddy Sep 2, 2026 to now63
- General counselMichael David Hutchinson Nov 25, 2022 to now64
- General counselKeyna Pidcock Skeffington Jul 27, 2017 to Sep 19, 202265
Products and brands
- medical device
Listed on Wikidata.1
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Cyberonics Netherlands CV Netherlands6
- LIVN Irishco 2 UC Ireland6
- LivaNova (China) Medical Technology Co. Ltd China6
- LivaNova (Thailand) Ltd Thailand6
- LivaNova Australia PTY Limited Australia6
- LivaNova Austria GmbH Austria6
- LivaNova Belgium N.V. Belgium6
- LivaNova Brasil Comércio e Distribuição de Equipamentos Médico-hospitalares Ltda Brazil6
- LivaNova Canada, Inc. Canada6
- LivaNova Chile SpA Chile6
- LivaNova Colombia Sas Colombia6
- LivaNova Deutschland GmbH Germany6
- LivaNova Espana, S.L. Spain6
- LivaNova Finland Oy Finland6
- LivaNova Holding S.r.l. Italy6
- LivaNova Hong Kong Limited Hong Kong6
- LivaNova IP Limited United Kingdom6
- LivaNova India Private Limited India6
- LivaNova Japan K.K. Japan6
- LivaNova Malaysia Sdn. Bhd. Malaysia6
- LivaNova Nederland N.V. Netherlands6
- LivaNova Norway AS Norway6
- LivaNova Plc United Kingdom6
- LivaNova Plc (Italian Branch) Italy6
All 35 listed subsidiaries
- LivaNova Poland Sp. Z o.o. Poland6
- LivaNova Regional Headquarter Company Saudi Arabia6
- LivaNova SAS France6
- LivaNova Singapore Pte Ltd Singapore6
- LivaNova Site Management S.r.l. Italy6
- LivaNova Switzerland SA Switzerland6
- LivaNova Taiwan Co. Ltd Taiwan6
- LivaNova Turkey Medikal Limited Sirketi Turkey6
- LivaNova UK Limited United Kingdom6
- Sorin Group Italia S.r.l. Italy6
- Sorin Group Rus LLC Russia6
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- Sand Holdco PlcApr 20, 2015 to Jun 12, 20155
Timeline
- Aug 5, 20268-K Results of operations66
- Jun 11, 20268-K Shareholder vote67
- May 6, 20268-K Results of operations68
- Feb 25, 20268-K Results of operations69
- Jan 14, 20268-K Executive or director change70
- Nov 5, 20258-K Results of operations71
- Sep 4, 20258-K Executive or director change72
- Aug 6, 20258-K Results of operations73
- Jun 11, 20258-K Executive or director change; Shareholder vote74
- May 21, 20258-K Regulation FD disclosure75
- May 7, 20258-K Results of operations76
- Mar 17, 20258-K Regulation FD disclosure77
- Mar 4, 2024New chief executive Vladimir Makatsaria becomes CEO16
- Dec 19, 2023New chief executive William A. Kozy becomes CEO17
- Nov 8, 2016New chief executive Damien McDonald becomes CEO18
- Oct 22, 2015New chief executive Andre Michel Ballester becomes CEO19
- 2015Founded Founded in London1
Calendar
Coming up
- Nov 4, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $0.97 a share, on Nov 5, 2025.78
When it reported results
- Aug 5, 2026Reported quarterly or annual results66
- May 6, 2026Reported quarterly or annual results68
- Feb 25, 2026Reported quarterly or annual results69
- Nov 5, 2025Reported quarterly or annual results71
- Aug 6, 2025Reported quarterly or annual results73
- May 7, 2025Reported quarterly or annual results76
- Feb 25, 2025Reported quarterly or annual results79
- Oct 30, 2024Reported quarterly or annual results80
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
323 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 60 major events, 162 insider forms, 20 large holders, 61 other. The latest 20:
- Sep 16, 20264 EDGAR
- Sep 14, 20264 EDGAR
- Sep 10, 2026144 EDGAR
- Sep 8, 20264 EDGAR
- Sep 4, 2026144 EDGAR
- Sep 2, 2026144 EDGAR
- Sep 2, 20264 EDGAR
- Sep 2, 20263 EDGAR
- Aug 31, 2026144 EDGAR
- Aug 13, 20264 EDGAR
- Aug 11, 2026144 EDGAR
- Aug 6, 2026SCHEDULE 13G EDGAR
- Aug 5, 2026IRANNOTICE EDGAR
- Aug 5, 202610-Q EDGAR
- Aug 5, 20263 EDGAR
- Aug 5, 20268-K EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
- Jun 17, 20264 EDGAR
The 323 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
25 open-market trades by officers, directors and large owners since October 2021: 1 buys and 24 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Bianchi FrancescoDirector | Sale | 3,500 | $78.01 | $273.0K | Form 4 |
| Sep 4, 2026 | Story BrookeDirector | Sale | 2,300 | $81.42 | $187.3K | Form 4 |
| Aug 31, 2026 | Bianchi FrancescoDirector | Sale | 1,650 | $79.72 | $131.5K | Form 4 |
| Aug 11, 2026 | Tezel AhmetChief Innovation Officer | Sale | 2,675 | $77.74 | $208.0K | Form 4 |
| Jun 15, 2026 | Bianchi FrancescoDirector | Sale | 1,200 | $80.19 | $96.2K | Form 4 |
| May 26, 2026 | Bianchi FrancescoDirector | Sale | 1,800 | $75.75 | $136.3K | Form 4 |
| Nov 18, 2025 | Story BrookeDirector | Sale | 250 | $53.94 | $13.5K | Form 4 |
| Aug 25, 2025 | Bianchi FrancescoDirector | Sale | 1,500 | $56.50 | $84.8K | Form 4 |
| Dec 11, 2024 | Bianchi FrancescoDirector | Sale | 1,250 | $50.99 | $63.7K | Form 4 |
| Sep 11, 2024 | Bianchi FrancescoDirector | Sale | 1,500 | $46.58 | $69.9K | Form 4 |
| Jun 3, 2024 | Moore Daniel JeffreyDirector | Sale | 56,623 | $60.12 | $3.4M | Form 4 |
| Mar 30, 2023 | McDonald DamienCEO | Sale | 2,220 | $42.55 | $94.5K | Form 4 |
| Dec 15, 2022 | McDonald DamienCEO | Sale | 2,220 | $54.56 | $121.1K | Form 4 |
| Apr 1, 2022 | Moore Daniel JeffreyDirector | Sale | 1,000 | $83.42 | $83.4K | Form 4 |
| Mar 29, 2022 | McDonald DamienCEO | Sale | 2,784 | $81.50 | $226.9K | Form 4 |
| Mar 2, 2022 | Moore Daniel JeffreyDirector | Sale | 1,000 | $80.00 | $80.0K | Form 4 |
| Feb 25, 2022 | Moore Daniel JeffreyDirector | Sale | 1,000 | $80.00 | $80.0K | Form 4 |
| Jan 3, 2022 | Moore Daniel JeffreyDirector | Sale | 1,000 | $85.93 | $85.9K | Form 4 |
| Dec 13, 2021 | McDonald DamienCEO | Sale | 2,784 | $81.50 | $226.9K | Form 4 |
| Dec 1, 2021 | Moore Daniel JeffreyDirector | Sale | 1,000 | $81.73 | $81.7K | Form 4 |
All 25 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- FMR LLCSCHEDULE 13G, 1 filing Aug 6, 202681
- INTEGRATED CORE STRATEGIES (US) LLCSCHEDULE 13G/A, 5 filings Apr 17, 2024 to Apr 30, 202682
- PRIMECAP MANAGEMENT CO/CA/SCHEDULE 13G/A, 6 filings Feb 10, 2022 to Feb 12, 202683
- BlackRockSCHEDULE 13G/A, 6 filings Jan 26, 2022 to Jul 18, 202584
- HARRIS ASSOCIATES L PSC 13G/A, 2 filings Feb 11, 2022 to Feb 14, 202385
SEC filer profile
How LivaNova is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARLivaNova PLC2
- CIK0001639691
- Employer ID (EIN)98-126815015
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company15
- Incorporated inEngland and Wales15
- Fiscal year endsDecember 312
- Industry code (SIC)3845 Electromedical & Electrotherapeutic Apparatus2
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
- Business address5220 Valiant Court, Gloucester Business Park, Gloucester, United Kingdom2
- Phone44020332506602
- Shares outstanding55,093,507 as of Jul 29, 202613
- Public float$2.5B as of Jun 30, 202515
- AuditorPricewaterhouseCoopers LLP, Houston, Texas PCAOB ID 238; it also attests to the company’s internal control over financial reporting15
- On EDGAR sinceApr 20, 20152
- Filings950 in all: 4 (474), 8-K (166), 3 (48), SC 13G/A (36), 10-Q (34), IRANNOTICE (29), 144 (16), 3/A (14)2
All 37 form types
4/A (14), DEFA14A (13), DEF 14A (11), SC 13G (11), SD (11), 10-K (10), UPLOAD (9), CORRESP (8), SCHEDULE 13G/A (7), S-8 (6), 8-K/A (5), ARS (4), PRE 14A (3), S-4/A (3), 10-K/A (2), 424B2 (2), NT 10-K (2), 10-KT (1), 10-KT/A (1), 10-Q/A (1), 424B3 (1), 8-K12B (1), 8-K12B/A (1), DEFR14A (1), EFFECT (1), NT 10-Q (1), S-3ASR (1), S-4 (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Feb 25, 2026
Quarterly report (10-Q) Aug 5, 2026
Proxy statement (DEF 14A) Apr 29, 2026
Latest 8-K (8-K) Aug 5, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Ordinary Shares - £1.00 par value per share | LIVN | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Feb 25, 2026 (Section 12(b) of the Exchange Act).15
Risk factors and legal proceedings
The risks LivaNova names in Item 1A of its 10-K filed Feb 25, 2026: 34 risks under these headings, as written.15
- Risks Relating to the Company’s Business and Operations
- LivaNova is subject to the risks of conducting business globally.
- Changes in global trade policies, including the imposition of tariffs, trade restrictions, export controls, sanctions, or other protectionist or retaliatory measures by the U.S. or other jurisdictions, may adversely affect LivaNova’s business, financial condition, and results of operations.
- Reductions and interruptions in LivaNova’s supply chain have had, and may continue to have, adverse effects on LivaNova’s business, results of operations, cash flows, and financial condition.
- Failure to protect, maintain, or upgrade LivaNova’s IT systems or products, or safeguard against cybersecurity incidents, service disruptions, or data corruption could have a material adverse effect on LivaNova’s business, results of operations, financial condition and reputation.
- The costs of complying with the requirements of U.S. federal and state and international laws and regulations pertaining to the privacy and security of personal information, including health-related information, and the potential liability associated with failure to comply with such laws and regulations, could have a material adverse effect on LivaNova’s business and results of operations.
- The global medical device industry is highly competitive, and LivaNova may be unable to compete effectively.
- The incorporation and use of AI technologies may present risks and challenges that could adversely affect LivaNova’s business, operations, and reputation.
- If LivaNova’s investments, alliances, acquisitions, or divestitures are unsuccessful, the Company may not realize the intended benefits.
- The continuing development of many of LivaNova’s products depends upon the Company maintaining appropriate working relationships with healthcare professionals.
- Quality issues with LivaNova’s processes, products, and services could harm the Company’s reputation for producing high-quality products and erode LivaNova’s competitive advantage, revenue, and market share.
- If LivaNova’s marketed medical devices are defective or otherwise pose safety risks, the FDA and similar non-U.S. governmental authorities could require their recall or initiate an enforcement action, or LivaNova could initiate a recall of the Company’s products or stop sales of products voluntarily.
The other 23 risks
- Failure to comply with U.S. and international product-related regulatory requirements could have a material adverse effect on LivaNova’s business, results of operations, cash flows, and financial condition.
- LivaNova’s success depends on its employees and the Company’s ability to attract and retain employees, succession plan, and successfully negotiate with local works councils.
- LivaNova’s products are subject to complex laws and regulations, and failure to obtain or maintain product approvals, clearance, or reimbursement may have a material adverse effect on LivaNova’s business, results of operations, cash flows, and financial condition.
- Global healthcare policy changes may have a material adverse effect on LivaNova’s business, results of operations, financial condition, and cash flows.
- Failure to comply with rules relating to reimbursement of healthcare goods and services, healthcare fraud and abuse, false claims, and other applicable laws or regulations may subject LivaNova to penalties and limit patient access to its devices, thereby adversely impacting the Company’s reputation and business operations.
- Failure to comply with anti-bribery laws could have a material adverse effect on LivaNova’s business and result in civil and/or criminal sanctions.
- The impact of pending or existing climate change may have a material adverse effect on LivaNova’s future operations.
- LivaNova may incur impairments of intangible assets, goodwill, and other long-lived assets that may adversely affect the Company’s financial results.
- Public health crises have had, and may continue to have, an adverse effect on LivaNova’s business, results of operations, cash flows, and financial condition, the nature and extent of which are uncertain and unpredictable.
- Shareholder activism and increased investor engagement could divert management’s attention, disrupt the Company’s operations, and adversely affect the business and share price.
- Legal, Regulatory, and Compliance Risks
- As a manufacturer of medical devices, LivaNova is exposed to product liability claims that could adversely affect its consolidated financial condition and tarnish the Company’s reputation.
- LivaNova is subject to heightened scrutiny on issues relating to sustainability, including environmental and sustainability laws and regulations, and the risk of environmental liabilities, violations, and litigation in multiple jurisdictions, any of which could have a material adverse effect on LivaNova’s reputation, business, results of operations, cash flows, financial condition, and liquidity.
- LivaNova is substantially dependent on patent and other proprietary rights, and failing to protect such rights or to be successful in litigation related to LivaNova’s rights or the rights of others may result in the Company’s payment of significant monetary damages and/or royalty payments, negatively impact LivaNova’s ability to sell current or future products, or prohibit the Company from enforcing its patent and other proprietary rights against others.
- Inadequate funding for U.S. federal government agencies and government shutdowns could negatively affect LivaNova’s business, results of operations, cash flows, and financial condition.
- Risks Related to LivaNova’s Indebtedness
- LivaNova may not have sufficient cash flow from its business operations to pay when due, or be able to raise the funds necessary to pay when due, amounts owed with respect to LivaNova’s indebtedness, which could adversely affect LivaNova’s business and results of operations.
- The conditional conversion feature of the 2029 Notes, if triggered, may adversely affect LivaNova’s liquidity and operating results.
- The effective interest rate of the 2029 Notes is significantly greater than the stated interest rate, which may result in volatility to the Company’s reported interest expense and financial results and could adversely affect the price at which LivaNova’s ordinary shares trade.
- The arbitrage or hedging strategy by purchasers of the 2029 Notes and Option Counterparties in connection with LivaNova’s 2029 Capped Calls may affect the value of LivaNova’s ordinary shares.
- LivaNova is subject to counterparty risk with respect to the 2029 Capped Calls.
- Risks Relating to Tax and LivaNova’s Jurisdiction of Incorporation
- LivaNova is incorporated in England and Wales and governed by their laws, which may afford less protection to shareholders than under U.S. laws.
- Changes in tax laws or exposure to additional income tax liabilities could have a material adverse effect on LivaNova’s results of operations and financial condition.
- As a public limited company incorporated under the laws of England and Wales, certain LivaNova capital structure decisions require shareholder approval, which may limit the Company’s flexibility to manage its capital structure.
- Transfers of LivaNova’s shares, other than those effected by means of the transfer of book-entry interests in DTC, may be subject to UK Stamp Duty or SDRT.
Legal proceedings
Information pertaining to certain material pending legal and regulatory proceedings and settlements is incorporated herein by reference to “Note 11. Commitments and Contingencies” in LivaNova’s consolidated financial statements and accompanying notes, beginning on page F-1 of this Report, and should be considered an integral part of “Part I, Item 3. Legal Proceedings” of this Report.
The opening of Item 3, Legal Proceedings.15
Links
- Websitewww.livanova.com1
- WikipediaLivaNova
- WikidataQ21592516
- SEC EDGARCIK 1639691
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataLivaNova on Wikidata
- 2SEC EDGARLivaNova filings on SEC EDGAR
- 3WikipediaLivaNova on Wikipedia
- 4
- 5SEC EDGARLivaNova filings on SEC EDGAR
- 6
- 7SEC EDGARLivaNova 10-K for fiscal 2025
- 8SEC EDGARLivaNova 10-K for fiscal 2019
- 9SEC EDGARLivaNova 10-K for fiscal 2020
- 10SEC EDGARLivaNova 10-K for fiscal 2021
- 11SEC EDGARLivaNova 10-K for fiscal 2022
- 12SEC EDGARLivaNova 10-Q for fiscal 2026
- 13SEC EDGARLivaNova 10-Q for fiscal 2026
- 14SEC EDGARLivaNova 10-K for fiscal 2019
- 15
- 16
- 17
- 18
- 19
- 20SEC EDGARStefano Folli, President
- 21SEC EDGARStephanie Bolton, President
- 22SEC EDGARFranco Poletti, President
- 23SEC EDGARMarco Dolci, President
- 24SEC EDGARRoy Khoury, President
- 25SEC EDGARRobert Jason Richey, President
- 26SEC EDGARJacques Gutedel, President
- 27SEC EDGARMichel Darnaud, President
- 28SEC EDGARRohan Hoare, President
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43SEC EDGARPiero Vecchi, VP & Controller
- 44
- 45SEC EDGARJette Nygaard-Andersen, Board member
- 46SEC EDGARDonald Zurbay, Board member
- 47SEC EDGARSusan M. Podlogar, Board member
- 48SEC EDGARDamien McDonald, Board member
- 49SEC EDGARPeter M. Wilver, Board member
- 50SEC EDGARBrooke Story, Board member
- 51SEC EDGARTodd Schermerhorn, Board member
- 52SEC EDGARSeng Stacy Enxing, Board member
- 53SEC EDGARWilliam A. Kozy, Board member
- 54SEC EDGARArthur L. Rosenthal, Board member
- 55SEC EDGARAndrea L. Saia, Board member
- 56SEC EDGARAlfred J. Novak, Board member
- 57SEC EDGARDaniel Jeffrey Moore, Board member
- 58SEC EDGARFrancesco Bianchi, Board member
- 59SEC EDGARHugh M. Morrison, Board member
- 60SEC EDGARRosario Bifulco, Board member
- 61SEC EDGARSharon O'Kane, Board member
- 62SEC EDGARStefano Gianotti, Board member
- 63SEC EDGARAnne M. Liddy, General counsel
- 64
- 65
- 66SEC EDGARResults of operations
- 67SEC EDGARShareholder vote
- 68SEC EDGARResults of operations
- 69SEC EDGARResults of operations
- 70SEC EDGARExecutive or director change
- 71SEC EDGARResults of operations
- 72SEC EDGARExecutive or director change
- 73SEC EDGARResults of operations
- 74
- 75SEC EDGARRegulation FD disclosure
- 76SEC EDGARResults of operations
- 77SEC EDGARRegulation FD disclosure
- 78NasdaqNasdaq calendar
- 79
- 80
- 81SEC EDGARFMR LLC SCHEDULE 13G on LivaNova
- 82
- 83
- 84SEC EDGARBlackRock SCHEDULE 13G/A on LivaNova
- 85